Bristol's Taxol Appeal Emphasizes Contribution Of Improved Dosing Regimen
Bristol-Myers Squibb's Taxol patent appeal hinges in part on the company's arguments that it should receive a reward for bringing an improved dosing schedule for paclitaxel to the public.
You may also be interested in...
Barr is focusing its appellate challenge of the Prozac patent ruling on double patent claims.
Ivax plans to launch a generic version of Bristol-Myers Squibb's Taxol (paclitaxel) without waiting for Bristol to appeal a Newark, N.J. federal court summary judgment that deems the majority of Bristol's paclitaxel patent claims invalid.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011